A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Aslan Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01614522
First received: May 22, 2012
Last updated: November 19, 2013
Last verified: November 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2013
  Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)